Xencor adds Barbara Klencke, M.D., to board; board expands to eight members

Xencor Inc

Board increased from 7 to 8 members; Dr. Klencke appointed effective Sept 15, 2023.
Dr. Klencke receives initial stock option with Black-Scholes value of $550,000, vesting over 3 years.
Annual cash retainer of $50,000 for board service; standard indemnification agreement.
Dr. Klencke previously CMO and CDO at Sierra Oncology; led Ojjaara approval for myelofibrosis.
Also serves on boards of eFFECTOR Therapeutics, Immune-Onc Therapeutics, and TScan Therapeutics.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Barbara Klencke

Director

XNCR · Xencor Inc

Effective: 2023-09-15
Filed: September 19, 2023, 7:59 PM ET

On September 15, 2023, the Board of Directors of the Company (the “Board”) was increased from seven to eight board members and Barbara Klencke, M.D., was appointed to serve as a new member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Barbara Klencke was appointed as Director at Xencor Inc.

Action: appointed
Role: Director

Exact text from the filing

On September 15, 2023, the Board of Directors of the Company (the “Board”) was increased from seven to eight board members and Barbara Klencke, M.D., was appointed to serve as a new member of the Board.

View on SEC.gov

Xencor Inc filing history →

Source: SEC EDGAR

accession 0001326732-23-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.